Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
hepatocellular carcinoma,unresectable hepatocellular carcinoma,durvalumab,tremelimumab,immune-mediated
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要